Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

OBJECTIVE: No evidence of progression or active disease (NEPAD) is a novel combined endpoint defined by the absence of both progression and inflammatory disease activity in primary progressive multiple sclerosis (PPMS). In the placebo‐controlled phase III ORATORIO study (NCT01194570), we investigate...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Neurol
Autors principals: Wolinsky, Jerry S., Montalban, Xavier, Hauser, Stephen L., Giovannoni, Gavin, Vermersch, Patrick, Bernasconi, Corrado, Deol‐Bhullar, Gurpreet, Garren, Hideki, Chin, Peter, Belachew, Shibeshih, Kappos, Ludwig
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220799/
https://ncbi.nlm.nih.gov/pubmed/30155979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ana.25313
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars